Hilleman Laboratories

Paddling with purpose – for an afternoon, the Hilleman team traded their pipettes for paddles to Kayak-and-Klean at Jurong Lake!   Armed with paddles and a shared sense of purpose for a cleaner environment, we set out to collect trash from the beautiful lake. Our dedicated team collected nearly 40 kilograms of trash, ranging from plastic bottles to discarded food wrappers!   Witnessing our colleagues come together to make a tangible difference for the community was truly inspiring and it served as a valuable reminder of the positive impact we can achieve as One Hilleman.   #hillemanlabs #kayakandklean #onehilleman 

Congratulations to our partner, the Developing Countries Vaccine Manufacturers Network (DCVMN International) and CEO Rajinder Suri on reaching a remarkable milestone – 25 years of advancing public health through driving innovation, enhancing access to life-saving vaccines, and strengthening the vaccine manufacturers in developing nations! Over the years, DCVMN has made tremendous strides in improving global vaccine access, particularly in LMICs. The DCVMN’s unwavering commitment to affordable, high-quality vaccines has not only protected countless lives but also reshaped the landscape of global immunization. By empowering developing countries to become self-reliant in vaccine production, DCVMN has championed the health needs of vulnerable populations and reinforced global health security. With the ever-growing challenges of emerging diseases and public health crises, the DCVMN remains a critical player in ensuring that no community is left behind in the fight against preventable diseases. Hilleman Labs is proud to support and partner with a dedicated organization committed to improving public health and we look forward to continuing our journey together toward a healthier, more equitable world. #DCVMN25years #hillemanlabs #vaccineequity

Imagine a world where the antibiotics we rely on for common infections, surgeries, and cancer treatments no longer work. Antimicrobial Resistance (AMR) is one of the top global public health and development threats, disproportionately burdening LMICs most. AMR arises from the misuse and overuse of antimicrobials, leading bacteria, fungi, or viruses to become resistant to the drugs used to treat them. This puts millions of lives at risk, especially in regions with already limited healthcare access. Staying informed and aware is crucial in supporting global efforts in protecting such vulnerable communities. Find out more below about the severity of AMR on public health and future global action we can expect in tackling against its risks. #hillemanlabs #AMR #antimicrobialresistance

From Lab to Leadership: introducing Sharrada Subramaniam, PhD! As Assistant Director of Business Development at Hilleman Labs, Sharrada's work spans the entire spectrum of vaccine development, manufacturing, and commercial activities—facilitating strategic partnerships and managing key relationships. Find out more about her journey from lab to leadership and what drives her to continue pushing boundaries! #hillemanlabs #employeefeature #businessdevelopment

A throwback to the recent Technology Transfer Training Programme – we are happy to share a compilation of participants’ feedback on the programme! Their dedication, curiosity, and passion have been truly inspiring. By empowering such talent with the skills needed for successful tech transfer, we push closer to ensuring that life-saving vaccines reach the communities that need them the most. We are grateful for the opportunity to share our expertise and contribute to advancing vaccine innovation and expanding global vaccine access! #hillemanlabs #techtransfertraining4 #technologytransfer

Hilleman Laboratories recently had the pleasure of hosting participants from SingHealth Duke-NUS Global Health Institute's Infectious Diseases and Global Health course for a lab tour and a visit to ACES. The visiting group comprised Associate Consultants and Nurse Clinicians - professionals who are at the forefront of healthcare delivery. The shared focus on infectious diseases and global health made the tour particularly meaningful, allowing us to showcase our cutting-edge research and vaccine development processes that directly contribute to global health, especially in LMICs. By engaging with the next generation of healthcare professionals, we aim to inspire, collaborate and advance our shared goal of improving global health outcomes. Together, let's continue to innovate and strive towards a healthier future for all!   #hillemanlabs #infectiousdiseases #vaccineequity

Last month the Hilleman team celebrated Singapore’s National Day with a nostalgic trip down memory lane, igniting friendly competition through old-school games that rekindled the joys of childhood. We revisited a series of classic games like chapteh, five stones, hopscotch, marbles and country rubber - the last one may sound odd but it sure was a favourite pastime in classrooms! Cheering each other on, we were delighted to see that the games revealed many hidden talents of our colleagues!   The festivities were surely not complete without an array of local delicacies and tasty snacks. Food is always a great way to enjoy the local culture, and it was especially meaningful to share this special day with all of our colleagues!   The simple celebration perfectly captured our One Hilleman culture, fostering a sense of community and strengthening our bonds and camaraderie as a team. Here's to more joyous occasions and creating lasting memories with team Hilleman!   #hillemanlabs #nationalday #onehilleman

It’s the 105-year anniversary of the birth of Dr. Maurice Hilleman today and here at Hilleman Laboratories in Singapore, we’re reflecting on an extraordinary week for us, with the launch of a novel oral vaccine to tackle cholera. Dr. Hilleman (August 30th, 1919–2005) stands as one of the most influential pioneers in vaccine science, whose contributions have profoundly shaped global health and medicine. His legacy is reflected in the countless lives saved by the numerous vaccines he developed and the significant advancements in vaccine research and development that followed. We are proud to be part of his lasting legacy, developing affordable vaccines and biologics against infectious diseases prevalent in low- and middle-income countries. This includes our work on the development of a new oral cholera vaccine (OCV) that was launched earlier this week by our licensing partner Bharat Biotech following extensive international collaboration involving the team at Hilleman Laboratories, Wellcome Trust, MSD, University of Gothenburg and Gotovax AB. You can read more about that announcement here: https://lnkd.in/dBPQ27-4 As we look ahead, we are committed to building on the foundations laid by Dr. Hilleman, fostering global partnerships, and advancing vaccine development and access. #GlobalHealth #VaccineEquity #HillemanLabs

We are delighted to share the news of HILLCHOL®, a breakthrough oral cholera vaccine (OCV) that has just been launched in Hyderabad, India. Pushing the boundaries of innovation, the collaborative and strategic pathway established for this new vaccine involved a number of forward-thinking partners - University of Gothenburg and its spin-off biopharma company, Gotovax AB, our founders MSD and Wellcome Trust, and Bharat Biotech who has just launched the vaccine in India. Bharat Biotech will now pursue World Health Organization pre-qualification to make the vaccine available to low- and middle-income countries (LMICs) where the need is great. HILLCHOL® is part of a broader portfolio of vaccines being developed at our Singapore headquarters, with the potential to benefit those most in need, and especially for populations in LMICs. The initiative aligns with Hilleman Laboratories' commitment to advancing public health and promoting health equity, including identifying affordable vaccines to tackle unmet medical needs. You can find out more about the announcement here: https://lnkd.in/dBPQ27-4 #GlobalHealth #VaccineEquity #InfectiousDiseases #InternationalPartnerships #HillemanLabs

Last week the World Health Organization declared a Public Health Emergency of International Concern (PHEIC) regarding the mpox outbreak in the Democratic Republic of Congo and neighboring African countries. Staying informed about the disease, symptoms, transmission, and preventive measures is crucial for global resilience against mpox.    At Hilleman Laboratories, we are committed to our public health mission to develop affordable vaccines against infectious diseases prevalent in LMICs. With our expertise in vaccine development and capabilities of our ACES facility, we stand ready to leverage our platforms to support the global health response. Let's join global efforts in strengthening preparedness and find out more about the disease to remain vigilant and collectively save lives.    #hillemanlabs #outbreakpreparedness #mpoxawareness